MS and Demyelinating Disorders

The director of Pediatric MS and Wellness at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine describes her study on shared medical appointments and the intricacies of integrating them into the common care realm.

Further results of the SPI2 trial will be presented at the upcoming American Academy of Neurology 2020 Annual Meeting in Toronto.

The label expansion now allows patients who require non-brain MRI monitoring to receive treatment with the stimulation device.

Data collected with a tracking scanning laser ophthalmoscope suggests that the small, jerk-like, involuntary eye movements that occur during prolonged visual focus can provide measurements of disability and disease worsening in MS.

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, discussed the challenges of current measurements and the need to adjust the reading of progressive MS.

The director of the Partners Pediatric MS Center at Massachusetts General Hospital for Children provided insight on the consequences of incomplete relapse recovery in multiple sclerosis.

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.

Neurology News Network for the week ending March 7, 2020.

The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.

A 6136-patient comparative study of fingolimod, rituximab, and natalizumab suggested that the former was associated with a borderline‐significant increased risk of cancer compared to the general population.